Association of nonselective β blockers with the development of hepatocellular carcinoma in liver cirrhosis: a meta-analysis - PubMed
4 hours ago
- #hepatocellular carcinoma
- #nonselective β blockers
- #liver cirrhosis
- Nonselective β blockers (NSBBs) may reduce the risk of hepatocellular carcinoma (HCC) in liver cirrhosis patients.
- Meta-analysis of 24 studies showed NSBBs significantly reduced HCC risk (RR=0.86; P=0.048).
- Subgroup analyses indicated reduced HCC risk with carvedilol (RR=0.72), nadolol (RR=0.86), and high-dose propranolol (>40 mg, RR=0.28).
- Protective effect was observed in studies from America (RR=0.83) and Europe (RR=0.72).
- NSBBs did not show protective effects in patients receiving prophylaxis for variceal bleeding.
- Future research should focus on personalized prevention strategies.